Dong-A ST and Beactica expand their research and licence agreement to develop new cancer treatments
Seoul, South Korea and Uppsala, Sweden – 12 March 2019Dong-A ST Co., Ltd. (170900: Korea SE), the Korean pharmaceutical company, and Beactica AB, the Swedish drug discovery company, today announced an expansion of their research and licensing agreement. The collaboration – which was initiated in October 2016 – is now expanded with an aim to jointly identify and develop novel small molecules targeting a protein–protein interaction of therapeutic relevance for immuno-oncology. The partnership further builds on Beactica's unique early-stage lead generation capabilities and DONG-A ST's